Janux Therapeutics, Inc.: Guggenheim assumes coverage with buy rating; target price $55
JANX•Guggenheim assumed coverage of Janux Therapeutics with a buy rating and a $55 target price.
Related News
CubicPV signs US solar patent licensing agreement with First Solar
FSLR•
Hershey: JP Morgan cuts target price to $166 from $183
HSY•
Piper Sandler cuts Twilio target price to $226 from $247
TWLO•
Eli Lilly: Jefferies raises target price to $1,610 from $1,440
LLY•
Pinterest: Jefferies cuts target price to $20 from $24
PINS•